06978 IMMUNOTECH-B
- 3.310
- -0.060-1.78%
IMMUNOTECH-B News
Immunotech Biopharm Posts Nearly 335 Million Yuan Loss in 2023
Immunotech Biopharm (HKG:6978) reported a loss and total comprehensive expense attributable to owners of approximately 334.8 million yuan for the year ended Dec. 31, 2023, compared with a loss of 318.
Yongtai Bio-B (06978.HK)'s annual loss increased to 335 million yuan
Gelonghui, March 28, 丨 Yongtai Bio-B (06978.HK) announced that for the year ended December 31, 2023, the company's other revenue increased by about RMB 1.4 million or about 15.4% from about RMB 9.1 million in the previous year to about RMB 10.5 million. R&D expenditure increased by approximately RMB 1.1 million, or approximately 0.6%, from approximately RMB 176.2 million in the previous year to approximately RMB 177.3 million in the same year. Total loss and overall expenses during the year increased by approximately RMB321.1 million for the year ended 31 December 2022 by approximately RMB14
Yongtai Bio-B (06978) Announces 2023 Annual Results with R&D Expenses of 177 Million Yuan to Accelerate Research on Expanded Indications for EAL
Yongtai Bio-B (06978) disclosed the 2023 annual results announcement. The company achieved about 1 other revenue during the reporting period...
IMMUNOTECH-B: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
Yongtai Bio-B (06978.HK) plans to hold a board meeting on March 28 to approve the annual results
Gelonghui March 18 | Yongtai Bio-B (06978.HK) announced that the company plans to hold a board meeting on March 28, 2024 (Thursday) to consider and approve (including) the annual results of the company and its subsidiaries for the year ended 31 December 2023 and their announcements.
IMMUNOTECH-B: DATE OF BOARD MEETING
Changes in Hong Kong stocks | Yongtai Bio-B (06978) rose more than 8%. The company recently joined hands with Corning to expand product commercialization cooperation
The Zhitong Finance App learned that Yongtai Bio-B (06978) rose more than 8%. As of press release, it had risen 8.41% to HK$3.61. According to news, Yongtai Biotech and Corning signed a memorandum of business cooperation in Beijing on March 1. According to reports, with the signing of the Memorandum of Business Cooperation, the two sides will carry out deeper cooperation in the development and marketing of customized products, testing laboratories, new products, etc., to promote the commercialization and implementation of Yongtai's important R&D pipelines. A previous research report by Societe Generale Securities pointed out that cellular immunotherapy has grown rapidly in recent years and has shown great potential. The company is deeply involved in cellular immunotherapy
Yongtai Bio-B (06978) joins hands with Corning to expand product commercialization cooperation
This time, a memorandum of business cooperation was signed to prepare the two sides to expand commercialization of Yongtai products.
Immunotech Biopharm Obtains Clinical Trial Nod in China for Leukemia Drug
Immunotech Biopharm (HKG:6978) said the Centre for Drug Evaluation of China's National Medical Products Administration has granted clinical trial approval for the firm's aT19 injection. Phase I clinic
Yongtai Bio-B (06978.HK): Drug Evaluation Center Approves AT19 Injection New Drug Phase I Clinical Trial (IND) Application
Gelonghui, Feb. 19 | Yongtai Bio-B (06978.HK) announced that the company has received approval from the Drug Evaluation Center (Drug Evaluation Center) of the China Drug Administration (Drug Evaluation Center) for the Phase 1 Clinical Trial (IND) application for aT19 injection. AT19 injection is an injection targeting CD19 chimeric antigen receptor T cells (CAR-T cells) used sequentially to prevent CD19 positive recurrence in patients under 25 with recurrent refractory B-cell-derived acute lymphocytic leukemia (B-ALL). The goal of this injection is to address CD19-targeting CAR-T cells against B
Yongtai Bio-B (06978) was successfully selected for the 2023 “one-stop” application demonstration direction and promotion agency list of key products and processes
Yongtai Biotech was successfully selected as the recommended agency for the key application demonstration direction of “activated autolymphocyte products”.
Announcement selection: Great Wall Motor's sales last month increased by more than 40% year on year; China Railway Construction recently won a bid of 73.298 billion yuan for a major project
C&D International Group: The cumulative contract sales amount in 2023 was about 137.96 billion yuan, an increase of 13.5% over the previous year; Kingsley Biotech: Legend Biotech and Novartis completed a global licensing agreement.
Chinese Drug Regulator Accepts Immunotech Biopharm's Application for AT19 Injection
China's National Medical Products Administration accepted Immunotech Biopharm's (HKG:6978) investigational new drug application for the aT19 injection. The biotechnology company developed the drug as
Yongtai Biotech B (06978) Receives Notice of Acceptance of New Drug Research Application for At19 Injection
According to the Zhitong Finance App, Yongtai Biotech B (06978) issued an announcement. The company has received an acceptance notice from the State Drug Administration regarding the study of new AT19 injectable drugs (acceptance number: CXSL2300808). AT19 injection is an injection that targets CD19 chimeric antigen receptor T cells (CAR-T cells) that target CD19 and is used sequentially after treating acute lymphocytic leukemia (B-ALL) derived from recurrent refractory B cells to prevent recurrent CD19 positive recurrence. The goal of this injection is to address the possibility of CD19 after B-ALL treatment with CAR-T cells targeting CD19
Selected Glonghui Announcements (Hong Kong Stocks) | City of Dreams International Development: City Boya Entertainment's total operating revenue for the third quarter increased by about 321% to US$1.02 billion
[Today's Focus] City BoA Development (00200.HK): City BoA Entertainment's total operating revenue for the third quarter increased by about 321% to US$1.02 billion, and announced that the total operating revenue of the company's subsidiary, the third quarter of 2023, was US$1.02 billion, an increase of about 321% over the same period in 2022. The increase in total operating income was mainly due to improvements in the performance of all of its gaming divisions and non-gaming operations since Macau eased epidemic prevention restrictions in January 2023 and the opening of the second phase of Studio City. City Expo in the third quarter of 2023
Immunotech Biopharm Enrolls First Patient in Clinical Trial of Lymphoma Drug
Immunotech Biopharm (HKG:6978) enrolled the first patient in its Phase I clinical trial of denocabtagene ciloleucel injection (DCI) in mainland China earlier today, Nov. 7. The biotech firm expects to
Yongtai Bio-B (06978.HK): The first patient enrolled in the phase I clinical trial of Dinorancel injection
Gelonghui November 7 | Yongtai Biotech B (06978.HK) announced that the company has enrolled the first patient in the phase I clinical trial of Dinoroncet Injection (“DCI”) in China on November 7, 2023, marking a milestone in the development of the products being developed by the Group. DCI (previously known as RC19D2, CAR-T-19-D2, and CAR-T-19-DNR) is a protein that targets the CD19 antigen and antagonizes the TGF-ß downstream signaling pathway. It is used as an injection to treat patients with recurrent and refractory diffuse large B-cell lymphoma (“DLBCL”). The goal of this injection
IMMUNOTECH-B: 2023 INTERIM REPORT
New open source (300109.SZ): Participating companies' cell therapy products to prevent recurrence of liver cancer after surgery are included as a breakthrough treatment variety
New Open Source (300109.SZ) announced that the company's shareholding company Yongtai Biopharmaceutical Co., Ltd. (“Yongtai Biotech for short...
China Grants Breakthrough Therapy Designation to Immunotech's Liver Cancer Medication; Shares Fall 5%
China's medical products administrator granted breakthrough therapy designation to Immunotech Biopharm's (HKG:6978) EAL medication for the prevention of postsurgical liver cancer, a Tuesday filing sai
Analysis
Price Target
No Data
